Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05194293

Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer

Stage III Hepatocellular Carcinoma AJCC v8 Clinical Trial

Official title:
Neoadjuvant Regorafenib Plus Durvalumab (MEDI4736) in Patients With High-Risk Hepatocellular Carcinoma

Clinical Trial Summary

This phase II trial tests whether regorafenib and durvalumab work to shrink tumors in patients with high-risk liver cancer. Regorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Giving regorafenib and durvalumab may work better in treating patients with high-risk liver cancer.

Clinical Trial Description

PRIMARY OBJECTIVE: I. To assess the overall response rate (ORR) at 16 weeks post registration. SECONDARY OBJECTIVES: I. To assess the rate of patients who undergo surgery during the course of the study. II. To assess the safety and tolerability of the combination therapy of regorafenib plus durvalumab. III. To assess the effect of combination therapy on overall survival. IV. To assess the effect of combination therapy on progression-free survival (PFS) in patients that do not undergo resection. V. To assess the effect of combination therapy on recurrent-free survival (RFS) in patients that have resection. VI. To assess the rate of pathologic complete response. CORRELATIVE RESEARCH OBJECTIVE: I. Analyze the effect of regorafenib and durvalumab on immune biomarkers in the tumor microenvironment and systemic circulation. OUTLINE: Patients receive regorafenib orally (PO) once daily (QD) on days 1-21 and durvalumab intravenously (IV) on day 1. Treatment repeats every 28 days for a maximum of 2 years from registration or until decision to proceed to surgery, disease progression, excessive toxicity, or patient withdrawal. After completion of study treatment, patients are followed every 90 days for 3 years. ;

Study Design

Related Conditions & MeSH terms

  • Carcinoma
  • Carcinoma, Hepatocellular
  • Stage IB Hepatocellular Carcinoma AJCC v8
  • Stage II Hepatocellular Carcinoma AJCC v8
  • Stage III Hepatocellular Carcinoma AJCC v8
  • Stage IIIA Hepatocellular Carcinoma AJCC v8
Clinical Trial Details
NCT number NCT05194293
Study type Interventional
Source Academic and Community Cancer Research United
Contact
Status Recruiting
Phase Phase 2
Start date June 29, 2023
Completion date December 5, 2028
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT03942328 - Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer Phase 1/Phase 2
Terminated NCT03695250 - BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer Phase 1/Phase 2
Active, not recruiting NCT03896646 - Radioembolization for HCC Patients With Personalized Yttrium-90 Dosimetry for Curative Intent (RAPY90D) N/A
Active, not recruiting NCT04514484 - Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV Phase 1
Recruiting NCT05168163 - Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer Phase 2
Recruiting NCT05269381 - Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors Phase 1
Recruiting NCT05791448 - AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease Phase 1
Active, not recruiting NCT04175912 - Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver Phase 2
Recruiting NCT04022746 - An Investigational Scan (Magnetic Resonance Elastography) in Detecting Treatment Response in Patients With Advanced Liver Cancer N/A
Recruiting NCT05176223 - 68Ga PSMA PET Imaging for the Treatment of Advanced Liver Cancer Phase 2
Recruiting NCT05199285 - A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab Phase 2
Suspended NCT04380545 - Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer Phase 1/Phase 2
Recruiting NCT04430452 - Hypofractionated Radiotherapy Followed by Durvalumab With or Without Tremelimumab for Liver Cancer After Progression on PD-1 Inhibition Phase 2
Withdrawn NCT05157451 - Y-90 Versus SBRT for Inoperable HCC Phase 2
Completed NCT01176604 - Yttrium Y 90 Glass Microspheres in Treating Patients With Unresectable Hepatocellular Carcinoma N/A
Recruiting NCT04605731 - Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer Phase 1
Active, not recruiting NCT04805788 - Stereotactic Body Proton Radiotherapy for the Treatment of Liver Cancer Phase 2
Recruiting NCT05092373 - Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax Phase 1
Recruiting NCT05103904 - Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant Phase 2
Active, not recruiting NCT03439891 - Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer Phase 2